Literature DB >> 17259346

A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents.

Daniel R McNeill1, David M Wilson.   

Abstract

Apurinic/apyrimidinic (AP) endonuclease 1 (APE1) is the primary enzyme in mammals for the repair of abasic sites in DNA, as well as a variety of 3' damages that arise upon oxidation or as products of enzymatic processing. If left unrepaired, APE1 substrates can promote mutagenic and cytotoxic outcomes. We describe herein a dominant-negative form of APE1 that lacks detectable nuclease activity and binds substrate DNA with a 13-fold higher affinity than the wild-type protein. This mutant form of APE1, termed ED, possesses two amino acid substitutions at active site residues Glu(96) (changed to Gln) and Asp(210) (changed to Asn). In vitro biochemical assays reveal that ED impedes wild-type APE1 AP site incision function, presumably by binding AP-DNA and blocking normal lesion processing. Moreover, tetracycline-regulated (tet-on) expression of ED in Chinese hamster ovary cells enhances the cytotoxic effects of the laboratory DNA-damaging agents, methyl methanesulfonate (MMS; 5.4-fold) and hydrogen peroxide (1.5-fold). This MMS-induced, ED-dependent cell killing coincides with a hyperaccumulation of AP sites, implying that excessive DNA damage is the cause of cell death. Because an objective of the study was to identify a protein reagent that could be used in targeted gene therapy protocols, the effects of ED on cellular sensitivity to a number of chemotherapeutic compounds was tested. We show herein that ED expression sensitizes Chinese hamster ovary cells to the killing effects of the alkylating agent 1,3-bis(2-chloroethyl)-1-nitrosourea (also known as carmustine) and the chain terminating nucleoside analogue dideoxycytidine (also known as zalcitabine), but not to the radiomimetic bleomycin, the nucleoside analogue beta-D-arabinofuranosylcytosine (also known as cytarabine), the topoisomerase inhibitors camptothecin and etoposide, or the cross-linking agents mitomycin C and cisplatin. Transient expression of ED in the human cancer cell line NCI-H1299 enhanced cellular sensitivity to MMS, 1,3-bis(2-chloroethyl)-1-nitrosourea, and dideoxycytidine, demonstrating the potential usefulness of this strategy in the treatment of human tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17259346     DOI: 10.1158/1541-7786.MCR-06-0329

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  56 in total

Review 1.  Overview of base excision repair biochemistry.

Authors:  Yun-Jeong Kim; David M Wilson
Journal:  Curr Mol Pharmacol       Date:  2012-01       Impact factor: 3.339

Review 2.  APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1.

Authors:  Mark R Kelley; Millie M Georgiadis; Melissa L Fishel
Journal:  Curr Mol Pharmacol       Date:  2012-01       Impact factor: 3.339

3.  Novel small-molecule inhibitor of apurinic/apyrimidinic endonuclease 1 blocks proliferation and reduces viability of glioblastoma cells.

Authors:  Aditi Bapat; Lateca S Glass; Meihua Luo; Melissa L Fishel; Eric C Long; Millie M Georgiadis; Mark R Kelley
Journal:  J Pharmacol Exp Ther       Date:  2010-05-26       Impact factor: 4.030

4.  Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction.

Authors:  Shinichi Someya; Wei Yu; William C Hallows; Jinze Xu; James M Vann; Christiaan Leeuwenburgh; Masaru Tanokura; John M Denu; Tomas A Prolla
Journal:  Cell       Date:  2010-11-24       Impact factor: 41.582

5.  Implications of apurinic/apyrimidinic endonuclease in reactive oxygen signaling response after cisplatin treatment of dorsal root ganglion neurons.

Authors:  Yanlin Jiang; Chunlu Guo; Michael R Vasko; Mark R Kelley
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

6.  Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth.

Authors:  Melissa L Fishel; Yanlin Jiang; N V Rajeshkumar; Glenda Scandura; Anthony L Sinn; Ying He; Changyu Shen; David R Jones; Karen E Pollok; Mircea Ivan; Anirban Maitra; Mark R Kelley
Journal:  Mol Cancer Ther       Date:  2011-06-23       Impact factor: 6.261

7.  Apurinic/apyrimidinic endonuclease 2 is necessary for normal B cell development and recovery of lymphoid progenitors after chemotherapeutic challenge.

Authors:  Jeroen E J Guikema; Rachel M Gerstein; Erin K Linehan; Erin K Cloherty; Eric Evan-Browning; Daisuke Tsuchimoto; Yusaku Nakabeppu; Carol E Schrader
Journal:  J Immunol       Date:  2011-01-12       Impact factor: 5.422

8.  Embryonic stem cells lacking the epigenetic regulator Cfp1 are hypersensitive to DNA-damaging agents and exhibit decreased Ape1/Ref-1 protein expression and endonuclease activity.

Authors:  Courtney M Tate; Melissa L Fishel; Julianne L Holleran; Merrill J Egorin; David G Skalnik
Journal:  DNA Repair (Amst)       Date:  2009-10-15

9.  Genome-wide analysis and proteomic studies reveal APE1/Ref-1 multifunctional role in mammalian cells.

Authors:  Carlo Vascotto; Laura Cesaratto; Leo A H Zeef; Marta Deganuto; Chiara D'Ambrosio; Andrea Scaloni; Milena Romanello; Giuseppe Damante; Giulio Taglialatela; Daniela Delneri; Mark R Kelley; Sankar Mitra; Franco Quadrifoglio; Gianluca Tell
Journal:  Proteomics       Date:  2009-02       Impact factor: 3.984

10.  Identification and characterization of inhibitors of human apurinic/apyrimidinic endonuclease APE1.

Authors:  Anton Simeonov; Avanti Kulkarni; Dorjbal Dorjsuren; Ajit Jadhav; Min Shen; Daniel R McNeill; Christopher P Austin; David M Wilson
Journal:  PLoS One       Date:  2009-06-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.